Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· July 29, 2026
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
View original at finance.yahoo.comSales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The Leqembi royalty to BioArctic was SEK 179 million in Q2 2026, an increase of approximately 10 percent compared to Q2 2025.
60% confidenceExcluding a one-time Q2 2025 stockpiling effect in China of approximately JPY 5.3 billion, royalty revenues in Q2 2026 grew approximately 43 percent year-over-year.
60% confidenceTotal sales of Leqembi were JPY 29.3 billion in the second quarter of 2026.
60% confidence
Cited in these Via News reports
- Biotech pipelines keep advancing on cash reserves while a risk-off tech market tightens the financing outlook →
- Biotech's clinical results are holding up while the AI money around it wobbles: what the European reader can verify →
- Europe's Biotech Cash Comes From Royalties and Hires While US Pipelines Hit Their Data Dates →
- Europe's Biotech Exposure Is Narrow but Real: A Swedish Royalty Stream Grows While the AI Funding Mood Sours →
- Europe's Biotech Footprint Is Thin in a Risk-Off Month, but BioArctic's Royalty Stream and Incyte's Cash Pile Show What Funding Stress Tests →
